Literature DB >> 22902944

Seven-year surveillance of nosocomial invasive aspergillosis in a French University Hospital.

Cécile Garnaud1, Marie-Pierre Brenier-Pinchart, Anne Thiebaut-Bertrand, Rebecca Hamidfar, Jean-Louis Quesada, Annick Bosseray, Bernadette Lebeau, Marie-Reine Mallaret, Danièle Maubon, Christel Saint-Raymond, Claudine Pinel, Virginie Hincky, Dominique Plantaz, Muriel Cornet, Hervé Pelloux.   

Abstract

OBJECTIVES: This study aims at describing the evolution of the epidemiology of invasive aspergillosis (IA) in a French University Hospital focussing on nosocomial cases, in order to assess the efficiency of the environmental preventive measures which were implemented.
METHODS: From 2003 to 2009, IA cases were reviewed monthly and classified according to the EORTC/MSG criteria and the origin of contamination.
RESULTS: Five proven and 65 probable IA cases were diagnosed. Most of the cases (74.3%) occurred in patients with haematological malignancies. Incidences of IA and nosocomial IA (NIA) were 0.106 and 0.032 cases per 1000 admissions, respectively. All the 21 NIA cases occurred in the absence of air treatment (laminar air flow facilities or Plasmair decontamination units) and/or during construction works. The 3-month and 1-year overall survival rates were 50.6% [38.2-61.7] and 31.1% [20-42.9] respectively, and did not differ according to the origin of contamination.
CONCLUSION: Nosocomial IA still accounted for a third of all IA cases diagnosed from 2003 to 2009 and mainly occurred in the absence of environmental protective measures, which were confirmed to be effective when applied. Our results show that extension and/or reinforcement of these measures is needed, especially in the haematology unit and during construction works.
Copyright © 2012 The British Infection Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22902944     DOI: 10.1016/j.jinf.2012.08.006

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  6 in total

1.  Evaluation of the Aspergillus Western blot IgG kit for diagnosis of chronic aspergillosis.

Authors:  A Oliva; P Flori; C Hennequin; J-C Dubus; M Reynaud-Gaubert; D Charpin; J M Vergnon; P Gay; A Colly; R Piarroux; H Pelloux; S Ranque
Journal:  J Clin Microbiol       Date:  2014-11-12       Impact factor: 5.948

2.  Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.

Authors:  Elodie Gautier-Veyret; Léa Bolcato; Matthieu Roustit; Stéphanie Weiss; Julia Tonini; Marie-Pierre Brenier-Pinchart; Muriel Cornet; Anne Thiebaut-Bertrand; Françoise Stanke-Labesque
Journal:  Antimicrob Agents Chemother       Date:  2019-09-23       Impact factor: 5.191

3.  Meteorological Factors Influence the Presence of Fungi in the Air; A 14-Month Surveillance Study at an Adult Cystic Fibrosis Center.

Authors:  Norman van Rhijn; James Coleman; Lisa Collier; Caroline Moore; Malcolm D Richardson; Rowland J Bright-Thomas; Andrew M Jones
Journal:  Front Cell Infect Microbiol       Date:  2021-11-26       Impact factor: 5.293

4.  Direct Molecular Diagnosis of Aspergillosis and CYP51A Profiling from Respiratory Samples of French Patients.

Authors:  Yanan Zhao; Cécile Garnaud; Marie-Pierre Brenier-Pinchart; Anne Thiébaut-Bertrand; Christel Saint-Raymond; Boubou Camara; Rebecca Hamidfar; Odile Cognet; Danièle Maubon; Muriel Cornet; David S Perlin
Journal:  Front Microbiol       Date:  2016-07-29       Impact factor: 5.640

5.  Bacteria killing nanotechnology Bio-Kil effectively reduces bacterial burden in intensive care units.

Authors:  P-R Hsueh; H-C Huang; T-G Young; C-Y Su; C-S Liu; M-Y Yen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-18       Impact factor: 3.267

Review 6.  Air pollution and health prevention: A document of reflection.

Authors:  E Bouza; F Vargas; B Alcázar; T Álvarez; A Asensio; G Cruceta; D Gracia; J Guinea; M A Gil; C Linares; P Muñoz; P Pastor; M L Pedro-Botet; X Querol; J Tovar; I Urrutia; F Villar; E Palomo
Journal:  Rev Esp Quimioter       Date:  2022-03-11       Impact factor: 2.515

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.